NASDAQ ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta ...

Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net ...

ANI Pharmaceuticals (ANIP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oren ...

For Q3, investors will be centered on the Alimera (ALIM) acquisition following its delayed closure, and the firm’s main spotlight during the earnings call will be on the FDA warning letter ...

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences.

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences. These ...

Competing interests Nicholas Beare—Advisory Board for Alimera Sciences, Consultancy for Abbvie, Expert Advisor for The Wellcome Trust on Research Supervisory Group for uveitis related grant. Patient ...